Metixeno [INN-Spanish] en es it fr

Metixeno [INN-Spanish] Brand names, Metixeno [INN-Spanish] Analogs

Metixeno [INN-Spanish] Brand Names Mixture

  • No information avaliable

Metixeno [INN-Spanish] Chemical_Formula

C16H16ClN3O3S

Metixeno [INN-Spanish] RX_link

http://www.rxlist.com/cgi/generic2/metolazone.htm

Metixeno [INN-Spanish] fda sheet

Metixeno_[INN-Spanish] FDA

Metixeno [INN-Spanish] msds (material safety sheet)

Metixeno [INN-Spanish] Synthesis Reference

No information avaliable

Metixeno [INN-Spanish] Molecular Weight

365.835 g/mol

Metixeno [INN-Spanish] Melting Point

256 oC

Metixeno [INN-Spanish] H2O Solubility

60.3 mg/L

Metixeno [INN-Spanish] State

Solid

Metixeno [INN-Spanish] LogP

2.784

Metixeno [INN-Spanish] Dosage Forms

Tablet for oral administration (0.5mg)

Metixeno [INN-Spanish] Indication

For the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.

Metixeno [INN-Spanish] Pharmacology

Metolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies.

Metixeno [INN-Spanish] Absorption

Peak blood levels are obtained within 2 to 4 hours of oral administration.

Metixeno [INN-Spanish] side effects and Toxicity

Symptoms of overdose include difficulty breathing, dizziness, dizziness on standing up, drowsiness, fainting, irritation of the stomach and intestines, and lethargy leading to coma.

Metixeno [INN-Spanish] Patient Information

No information avaliable

Metixeno [INN-Spanish] Organisms Affected

Humans and other mammals